MannKind Corporation (NASDAQ:MNKD) Files An 8-K Submission of Matters to a Vote of Security HoldersItem 5.07Submission of Matters to a Vote of Security Holders.
The following is a brief description of each matter voted upon at our 2018 Annual Meeting of Stockholders held on May 16, 2018 (the “Annual Meeting”), as well as the number of votes with respect to each matter.
| • | Our stockholders elected each of the seven individuals nominated by our Board of Directors to serve as directors until the next annual meeting of stockholders. The tabulation of votes in the election was as follows: |
|
Nominee |
Shares Voted For | Shares Withheld | Broker Non- Votes |
|
Michael Castagna |
23,160,193 | 2,315,283 | 78,420,505 |
|
Kent Kresa |
21,108,518 | 4,366,958 | 78,420,505 |
|
Ronald Consiglio |
22,279,248 | 3,196,228 | 78,420,505 |
|
Michael Friedman |
19,712,897 | 5,762,579 | 78,420,505 |
|
David H. MacCallum |
22,267,474 | 3,208,002 | 78,420,505 |
|
Henry L. Nordhoff |
22,140,483 | 3,334,993 | 78,420,505 |
|
James S. Shannon |
19,988,446 | 5,487,030 | 78,420,505 |
| • | Our stockholders approved our 2018 Equity Incentive Plan. The tabulation of votes on this matter was as follows: shares voted for: 18,814,553; shares voted against: 6,205,388; shares abstaining: 455,535; and broker non-votes: 78,420,505. |
| • | Our stockholders approved an amendment to our 2004 Employee Stock Purchase Plan to, among other things, increase the number of shares of common stock authorized for issuance under the 2004 Employee Stock Purchase Plan by 3,000,000 shares. The tabulation of votes on this matter was as follows: shares voted for: 21,069,308; shares voted against: 3,937,648; shares abstaining: 468,520; and broker non-votes: 78,420,505. |
| • | Our stockholders approved, on an advisory basis, the compensation of our named executive officers, as disclosed in our definitive proxy statement for the Annual Meeting, filed with the Securities and Exchange Commission on March 29, 2018. The tabulation of votes on this matter was as follows: shares voted for: 21,073,448; shares voted against: 3,882,466; shares abstaining: 519,562; and broker non-votes: 78,420,505. |
| • | Our stockholders ratified the selection of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December31, 2018. The tabulation of votes on this matter was as follows: shares voted for: 93,555,935; shares voted against: 9,457,990; shares abstaining: 882,056; and broker non-votes: 0. |
About MannKind Corporation (NASDAQ:MNKD)
MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a portable inhaler. AFREZZA utilizes its Technosphere formulation technology. Technosphere is a drug delivery platform that may allow the oral inhalation of a range of therapeutics. Technosphere powders are based on the Company’s fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created a range of breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format.
